The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients

Br J Clin Pharmacol. 1994 Jul;38(1):77-9. doi: 10.1111/j.1365-2125.1994.tb04325.x.

Abstract

The pharmacokinetics of fluconazole after a single 100 mg i.v. dose were studied in 10 healthy subjects (5 M; 5 F) and 10 HIV-positive patients (8 M; 2 F). The mean value of plasma clearance was 25% lower in the patient groups (17 +/- 6 (s.d.) vs 23 +/- 4 ml min-1; 95% CI of difference -11 to -0.7; P < 0.05). This difference may have been related to slightly reduced kidney function in the patient group (mean creatinine clearance -18%) but is unlikely to be clinically significant. Therefore, no adjustment of the dose of intravenously administered fluconazole appears to be necessary in AIDS patients without clinical signs of enteropathy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Acquired Immunodeficiency Syndrome / metabolism*
  • Adult
  • Chromatography, High Pressure Liquid
  • Creatinine / metabolism
  • Female
  • Fluconazole / administration & dosage
  • Fluconazole / blood
  • Fluconazole / pharmacokinetics*
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Male
  • Metabolic Clearance Rate

Substances

  • Fluconazole
  • Creatinine